Sixty-eight percent of patients in one pivotal arm achieved PASI 90 by Week 24 — and that number understates what makes the envudeucitinib Phase 3 readout clinically interesting. Alumis presented ONWARD1 and ONWARD2 data at the American Academy of Dermatology meeting showing that quality-of-life improvements and itch relief preceded skin clearance, with scalp psoriasis — notoriously resistant to oral agents — approaching clear or almost-clear status in roughly three-quarters of patients by Week 24. That sequence matters. Onset profile shapes how dermatologists counsel patients in the first weeks of therapy, and early symptom relief is increasingly what drives persistence on oral options competing against biologics.
The direct comparison point is deucravacitinib, the approved TYK2 inhibitor from Bristol Myers Squibb, which posted PASI 90 rates in the 53–58% range in its pivotal trials. Alumis is not running a head-to-head, and cross-trial comparisons carry all the usual caveats about patient populations and study design. But a PASI 90 ceiling around 68% positions envudeucitinib meaningfully above what the market currently associates with the TYK2 mechanism, and a PASI 100 rate of 41% in ONWARD1 approaches territory more commonly claimed by IL-17 or IL-23 biologics. That is the commercial argument Alumis is building toward an NDA submission targeted for Q4 2026.
The SLE readout arriving in Q3 2026 carries its own weight. Phase 2b topline data from the LUMUS trial will determine whether envudeucitinib can credibly expand into lupus — a far more heterogeneous and regulatory-demanding indication than psoriasis. TYK2 inhibition in SLE is biologically rational given the pathway’s role in type I interferon signaling, but the clinical translation has been harder to demonstrate consistently across the class. A positive LUMUS readout would do more than add an indication; it would validate the “TYK2 franchise” thesis that Alumis is now explicitly building its long-range strategy around. A miss would leave the company heavily concentrated in a psoriasis market it has not yet entered commercially.
With $569.5 million in cash extending runway into Q4 2027, Alumis has enough capital to absorb the NDA process and see the SLE data without an immediate financing overhang. The single marker worth tracking is the LUMUS Q3 readout — specifically whether the primary endpoint holds across the SLE disease activity measures that regulators have historically found most credible, because that result determines whether envudeucitinib is a single-indication oral psoriasis drug or the anchor of a multi-indication immunology platform.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
